Ensysce Biosciences, Inc.
NASDAQENSC short interest plunged 32% in one day to 7.7% of float, though shares shorted have surged 516% over the past week amid extreme borrowing costs at 104.5% APR.
Ensysce Biosciences heads into its May 20 earnings report with an unusually charged lending market — the defining feature of its current setup. The borrow story here is striking. Cost to borrow has risen to 122.7%…
ENSC heads into its May 20 earnings event carrying the most aggressive short-side lending profile it has seen all year — a violent, week-long repricing that leaves the stock at $0.28 and the borrow market in a state of…
Snapshot as of 2 Jul 2026
ENSC arrives at its May 13 earnings report in an unusual position: the stock is tiny, the short interest is negligible, yet borrowing its shares commands a rate that would embarrass many heavily contested names. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ENSC — free to start on ORTEX.
Sign up for free →Open ENSC on ORTEX